File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/lt.23901
- Scopus: eid_2-s2.0-84932186609
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Conference Paper: Impact of graft type on the survival outcome of salvage Liver Transplantation for recurrent Hepatocellular Carcinoma
Title | Impact of graft type on the survival outcome of salvage Liver Transplantation for recurrent Hepatocellular Carcinoma |
---|---|
Authors | |
Issue Date | 2014 |
Publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021 |
Citation | The 2014 Joint International Congress of ILTS, ELITA and LICAGE, London, UK., 4-7 June 2014. In Liver Transplantation, 2014, v. 20 suppl. S1, p. S360, abstract no. P-677 How to Cite? |
Abstract | Aim: To evaluate the prognostic influence of graft type on salvage liver transplantation (SLT) for recurrent hepatocellular carcinoma (HCC)
Methods: A retrospective analysis of 31 patients who underwent SLT for tumor recurrence after primary surgical treatment for HCC between year 2000-2011 was conducted. All the primary tumors were within USCF criteria. Survival analysis was conducted by Kaplan-Meier methods and compared between groups by log-rank test. P-value < 0.05 was considered significant.
Results:
A total of 22 patients received living-related SLT (LDSLT) and the remaining 9 patients received cadaveric-related SLT (DDSLT). 10 patients (LDSLT: n=7; DDSLT: n=3) underwent hepatectomy and 21 patients (LDSLT: n=15, DDSLT: n= 6) received radiofrequency ablation as primary treatment for HCC prior to SLT. 11 patients (LDSLT:n=9 vs. DDSLT:n=2, p=0.324) underwent SLT for recurrence beyond the UCSF criteria. 5 patients in each group received TACE as bridging treatment. LDSLT patients were significantly younger (age 53 vs. 58, p=0.046)) and had higher AFP levels (187.1 vs. 30.5ng/ml, p = 0.006) at first diagnosis of HCC than DDSLT patients. There was no significant difference with regard to primary tumor size (2.5 vs. 2.5cm), time to recurrence after primary treatment (15 vs. 8 months), recurrent tumor size (4.0 vs. 4.0cm) and number (n=2 vs. 2), and serum AFP level at recurrence (27.5 vs. 5.0ng/ml) between the two groups. The 1-, 3- and 5-year recurrence-free survival rates for LDSLT were 81.8%, 61.4% and 61.4%; and the corresponding survival rates for DDSLT were all 88.9% (p = 0.176).
Conclusion
Our study showed that both LDSLT and DDSLT attained satisfactory long-term survival benefit. Although statistically insignificant, DDSLT appeared to have a more favorable oncological outcome than LDSLT. Further studies with larger cohort are warranted to elucidate this issue. |
Description | Poster Session 3 - Recurrent Disease/Pathology: P-677 This free journal suppl. entitled: The ILTS 20th Annual International Congress |
Persistent Identifier | http://hdl.handle.net/10722/198643 |
ISSN | 2023 Impact Factor: 4.7 2023 SCImago Journal Rankings: 1.700 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, ACY | - |
dc.contributor.author | Chan, SC | - |
dc.contributor.author | Chok, KSH | - |
dc.contributor.author | Cheung, TT | - |
dc.contributor.author | Lo, CM | - |
dc.date.accessioned | 2014-07-07T08:29:35Z | - |
dc.date.available | 2014-07-07T08:29:35Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | The 2014 Joint International Congress of ILTS, ELITA and LICAGE, London, UK., 4-7 June 2014. In Liver Transplantation, 2014, v. 20 suppl. S1, p. S360, abstract no. P-677 | - |
dc.identifier.issn | 1527-6465 | - |
dc.identifier.uri | http://hdl.handle.net/10722/198643 | - |
dc.description | Poster Session 3 - Recurrent Disease/Pathology: P-677 | - |
dc.description | This free journal suppl. entitled: The ILTS 20th Annual International Congress | - |
dc.description.abstract | Aim: To evaluate the prognostic influence of graft type on salvage liver transplantation (SLT) for recurrent hepatocellular carcinoma (HCC) Methods: A retrospective analysis of 31 patients who underwent SLT for tumor recurrence after primary surgical treatment for HCC between year 2000-2011 was conducted. All the primary tumors were within USCF criteria. Survival analysis was conducted by Kaplan-Meier methods and compared between groups by log-rank test. P-value < 0.05 was considered significant. Results: A total of 22 patients received living-related SLT (LDSLT) and the remaining 9 patients received cadaveric-related SLT (DDSLT). 10 patients (LDSLT: n=7; DDSLT: n=3) underwent hepatectomy and 21 patients (LDSLT: n=15, DDSLT: n= 6) received radiofrequency ablation as primary treatment for HCC prior to SLT. 11 patients (LDSLT:n=9 vs. DDSLT:n=2, p=0.324) underwent SLT for recurrence beyond the UCSF criteria. 5 patients in each group received TACE as bridging treatment. LDSLT patients were significantly younger (age 53 vs. 58, p=0.046)) and had higher AFP levels (187.1 vs. 30.5ng/ml, p = 0.006) at first diagnosis of HCC than DDSLT patients. There was no significant difference with regard to primary tumor size (2.5 vs. 2.5cm), time to recurrence after primary treatment (15 vs. 8 months), recurrent tumor size (4.0 vs. 4.0cm) and number (n=2 vs. 2), and serum AFP level at recurrence (27.5 vs. 5.0ng/ml) between the two groups. The 1-, 3- and 5-year recurrence-free survival rates for LDSLT were 81.8%, 61.4% and 61.4%; and the corresponding survival rates for DDSLT were all 88.9% (p = 0.176). Conclusion Our study showed that both LDSLT and DDSLT attained satisfactory long-term survival benefit. Although statistically insignificant, DDSLT appeared to have a more favorable oncological outcome than LDSLT. Further studies with larger cohort are warranted to elucidate this issue. | - |
dc.language | eng | - |
dc.publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021 | - |
dc.relation.ispartof | Liver Transplantation | - |
dc.rights | Liver Transplantation. Copyright © John Wiley & Sons, Inc. | - |
dc.title | Impact of graft type on the survival outcome of salvage Liver Transplantation for recurrent Hepatocellular Carcinoma | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Chan, ACY: acchan@hku.hk | - |
dc.identifier.email | Chan, SC: chanlsc@hkucc.hku.hk | - |
dc.identifier.email | Chok, KSH: chok6275@hku.hk | - |
dc.identifier.email | Cheung, TT: cheung68@hku.hk | - |
dc.identifier.email | Lo, CM: chungmlo@hkucc.hku.hk | - |
dc.identifier.authority | Chan, ACY=rp00310 | - |
dc.identifier.authority | Chan, SC=rp01568 | - |
dc.identifier.authority | Chok, KSH=rp02110 | - |
dc.identifier.authority | Cheung, TT=rp02129 | - |
dc.identifier.authority | Lo, CM=rp00412 | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1002/lt.23901 | - |
dc.identifier.scopus | eid_2-s2.0-84932186609 | - |
dc.identifier.hkuros | 229865 | - |
dc.identifier.volume | 20 | - |
dc.identifier.issue | suppl. S1 | - |
dc.identifier.spage | S360, abstract no. P-677 | - |
dc.identifier.epage | S360, abstract no. P-677 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1527-6465 | - |